Loading…
2 companies · GEL, thousands · columns ordered by revenue
GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Revenue | 261,483 | 668,700 |
| EBITDA | 95,273 | 336,860 |
| Net profit | 95,273 | 336,860 |
| Total assets | 264,142 | 720,283 |
| n (companies reporting) | 2 | 2 |
GEL, thousands
| Company | FY 2023 | FY 2024 |
|---|---|---|
| Abulpharm | 134,251 | 341,277 |
| Shotapharm | 127,232 | 327,423 |
Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.
Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.